tiprankstipranks
InMed Pharmaceuticals (DE:MWG)
FRANKFURT:MWG
Holding DE:MWG?
Track your performance easily

InMed Pharmaceuticals (MWG) Income Statement

1 Followers

InMed Pharmaceuticals Income Statement

Last quarter (Q4 2024), InMed Pharmaceuticals's total revenue was $1.28M, a decrease of -44.48% from the same quarter last year. In Q4, InMed Pharmaceuticals's net income was $-1.94M. See InMed Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 24Jun 23Jun 22Jun 21Jun 16
Total Revenue
$ 4.60M$ 4.60M$ 4.14M$ -1.09M-$ 0.00
Cost of Revenue
$ 3.50M$ 3.50M$ 2.73M$ 545.89K--
Gross Profit
$ 1.10M$ 1.10M$ 1.40M$ -1.64M--
Operating Expense
$ 9.24M$ 9.24M$ 9.78M$ 15.65M$ 9.94M$ 1.84M
Operating Income
$ -8.13M$ -8.13M$ -8.38M$ -17.28M$ -9.94M$ -1.84M
Net Non Operating Interest Income Expense
$ 527.90K$ 527.90K$ 492.44K$ 96.09K$ 344.33K-
Other Income Expense
--$ -48.17K-$ 79.53K$ -25.00
Pretax Income
$ -7.67M$ -7.67M$ -7.93M$ -20.78M$ -10.20M$ -1.84M
Tax Provision
$ 7.10K$ 7.10K$ 13.10K---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -7.68M$ -7.68M$ -7.95M$ -20.78M$ -10.20M$ -1.84M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-----$ 67.20K
Total Expenses
---$ 16.20M$ -9.94M$ 1.84M
Net Income From Continuing And Discontinued Operation
$ -7.68M$ -7.68M$ -7.95M$ -20.78M$ -10.20M$ -1.84M
Normalized Income
$ -5.64M$ -5.64M$ -5.83M$ -11.80M$ -7.50M$ -1.84M
Interest Expense
------
EBIT
$ -7.67M$ -7.67M$ -7.93M$ -20.78M$ -9.84M$ -1.84M
EBITDA
$ -7.06M$ -7.06M$ -7.34M$ -20.27M$ -9.61M$ -1.77M
Currency in USD

InMed Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis